Rix, Peter J. External Entity


Sort by

Selected publications

  • Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.  Journal of clinical oncology : official journal of the American Society of Clinical Oncology2013 Academic Article GET IT
  • ARN-509: a novel antiandrogen for prostate cancer treatment.  Cancer research2012 Academic Article GET IT
    Times cited: 222